Miles Gerson

Global Head & President, Takeda Ventures

2024

Former Board Director: ImmPact Bio (Aquired by Lyell Immunopharma), Zelluna Immunotherapy (Listed on Euronext: ZLNA), Harness Therapeutics, Integra Therapeutics, Crosswalk Therapeutics, Catamaran Bio

Executive Investment Director & Partner

2023 - 2024

Senior Investment Director & Partner

2021 - 2023

Partner

2020 - 2021

Interim Head of GI Business Development

2021 - 2022

+ Served in a dual role capacity on an interim basis to support Takeda’s GI BD team while Takeda sourced a new team lead. + Managed BD transaction team for preclinical and clinical transactions for TAK’s GI Drug Development and Therapeutic Area Units + Led and guided negotiations of term sheets through to deal structuring for collaborations & licensing + Responsible for advising on strategic transactions and management of existing partnerships

Senior Director, Business Development & Legal Affairs; Corporate Counsel and Compliance Officer

2016 - 2020

Formerly miRagen Therapeutics (NASDAQ:MGEN) + Member of MGEN’s Senior Leadership Team - Advising on corporate and commercial strategy + Head of Legal - Managed internal attorney team and multiple outside counsel internationally - Responsible for all legal and business term negotiations for all operational elements at MGEN - Supported Investor Relations and SEC compliance during and after MGEN’s reverse merger and listing on NASDAQ + Head of Business Development - Lead negotiator for term sheets, deal structuring for collaborations, and licensing - Responsible for strategic partnering, deal diligence, asset valuation, and market assessment - Lead for all partnering outreach across multiple therapeutic areas: oncology, cardiology, neurology, autoimmunity, dermatology, diabetes, fibrosis and ophthalmology

Founder and Principal

2007 - 2020

+ Sole proprietor consultant specializing in investment diligence, negotiations, commercial assessment, strategic partnering, M&A, and business/corporate development for emergent, scientific & tech companies + 30+ investment diligences in companies that ultimately raised more than $450M in new funding

Vice President, Business & Corporate Development

2015 - 2016

+ Lead targeted collaboration and licensing negotiations for early stage startup + Responsible for market and competitive analysis, asset valuation, and market assessment

Managing Officer, Business Development

2012 - 2015

+ Engaged multiple large pharma partnership deals of greater than $100M + Developed advisory committee comprised of 40+ corporate and institutional venture groups + Installed financial and competitive analysis practices for advising and driving startup formation, large scale collaborations, and licensing negotiations + Back-to-back years of highest recorded annual metrics at UCLA in Invention Disclosures (20%Y/Y growth), Startup Formation, and New Licenses; and $15M increase in license revenue Y/Y

Director of Finance & Administration; Corporate Secretary

2010 - 2012

Formerly Surefire Medical now Trisalus Life Sciences (NASDAQ: TLSI) + Founding Management Team Member - Grew company from bootstrapped startup to multimillion dollar annual revenue with international distribution and in-house sales team + Coordinated the raise of Trisalus’ $6M+ Seed and Series A financing rounds + Managed Trisalus’ Capitalization, Financial Forecasting, Accounting, A/P, A/R, Financial Reporting, Taxation Filings, Human Resources, and Business licensing + Negotiated and managed legal agreements with all consultants, vendors, and suppliers

Venture Capital Analyst

2009 - 2011

+ Performed investment diligence for 8 of the fund’s 14 portfolio investments + Developed economic impact model of fund’s investments for presentation to Colorado State Assembly + Responsible for portfolio company management, including financial/strategic planning as interim-CFO, full-scale market characterization/valuation for strategic planning, and target product profile assessment/project planning

Associate (pro bono)

2009 - 2011

Executive Director

2005 - 2007